News & Updates

Show Multimedia Only

$Durable responses seen with axatilimab in recurrent/refractory GVHD$

Durable responses seen with axatilimab in recurrent/refractory GVHD

29 Jan 2024 by

The anti–CSF-R1 antibody axatilimab offers rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (GVHD) in the pivotal phase II AGAVE-201 trial.

Durable responses seen with axatilimab in recurrent/refractory GVHD

29 Jan 2024

One-time ceftriaxone cuts ventilator-associated pneumonia risk

28 Jan 2024

A single dose of ceftriaxone appears to reduce the risk of developing early ventilator-associated pneumonia (VAP) in patients with acute brain injury, according to the PROPHY-VAP study.

One-time ceftriaxone cuts ventilator-associated pneumonia risk

28 Jan 2024

Long-term steroid-free pemphigus remission achieved with frontline rituximab

28 Jan 2024 by

First-line treatment with rituximab appears to induce durable remission in patients with pemphigus, and this is achieved without corticosteroid therapy and any additional maintenance infusion of rituximab.

Long-term steroid-free pemphigus remission achieved with frontline rituximab

28 Jan 2024

Biologics effective, safe for inflammatory conditions of the pouch

28 Jan 2024

Use of biologics provides clinical benefits in patients with chronic, refractory inflammatory conditions of the pouch, with no new safety signals observed, reports a study. Moreover, infliximab appears more effective than adalimumab and vedolizumab for chronic antibiotic-refractory pouchitis (CARP).

Biologics effective, safe for inflammatory conditions of the pouch

28 Jan 2024

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

27 Jan 2024 by

In the treatment of chronic rhinosinusitis (CRS), exhalation delivery system with fluticasone (EDS-FLU) provides relief from symptoms while reducing intrasinus disease and the incidence of acute exacerbations, regardless of the presence of polyps, as shown in the phase III trials ReOpen1 and ReOpen2.

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

27 Jan 2024

Clinical outcomes vary among older adults taking antidepressants

27 Jan 2024

Use of commonly used antidepressants may result in different outcomes among older adults initiating this medication for depression, as shown in a study.

Clinical outcomes vary among older adults taking antidepressants

27 Jan 2024

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

Combining the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab appears to be efficacious and safe in the second-line treatment of metastatic esophagogastric adenocarcinoma, as shown in the phase II nonrandomized RAP trial.

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

27 Jan 2024 by

Low-dose calcium supplementation during pregnancy was noninferior to standard high-dose supplementation in preventing the risk of pre-eclampsia, according to two randomized clinical trials conducted in India and Tanzania.

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

27 Jan 2024

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

26 Jan 2024 by

In the treatment of older patients with nonvalvular atrial fibrillation (AF) who are considered ineligible for oral anticoagulants at the recommended therapeutic strength or the approved doses, the use of low-dose edoxaban helps reduce the risk of stroke or systemic embolism regardless of body weight, although this benefit comes with a slightly higher major bleeding events, according to the subgroup analysis of the phase III ELDERCARE‐AF trial.

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

26 Jan 2024

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective

26 Jan 2024

For patients who have undergone coronary artery bypass graft, initiating treatment with sacubitril/valsartan early is safe and appears to improve outcomes, as shown in an open-label study.

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective

26 Jan 2024

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Durable responses seen with axatilimab in recurrent/refractory GVHD

Durable responses seen with axatilimab in recurrent/refractory GVHD

One-time ceftriaxone cuts ventilator-associated pneumonia risk

One-time ceftriaxone cuts ventilator-associated pneumonia risk

Long-term steroid-free pemphigus remission achieved with frontline rituximab

Long-term steroid-free pemphigus remission achieved with frontline rituximab

Biologics effective, safe for inflammatory conditions of the pouch

Biologics effective, safe for inflammatory conditions of the pouch

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

Clinical outcomes vary among older adults taking antidepressants

Clinical outcomes vary among older adults taking antidepressants

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective